Cargando…

Identification of genes associated with castration-resistant prostate cancer by gene expression profile analysis

Prostate cancer (CaP) is a serious and common genital tumor. Generally, men with metastatic CaP can easily develop castration-resistant prostate cancer (CRPC). However, the pathogenesis and tumorigenic pathways of CRPC remain to be elucidated. The present study performed a comprehensive analysis on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Chui Guo, Li, Feng Xi, Pan, Song, Xu, Chang Bao, Dai, Jun Qiang, Zhao, Xing Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865838/ https://www.ncbi.nlm.nih.gov/pubmed/28901445 http://dx.doi.org/10.3892/mmr.2017.7488

Ejemplares similares

Gene Expression Profiling Analysis of Castration-Resistant Prostate Cancer
por: Wang, Xuelei, et al.
Publicado: (2015)

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
por: Li, Yan, et al.
Publicado: (2022)

Blood-based gene expression profiling in castrate-resistant prostate cancer
por: Gross, Mitchell E.
Publicado: (2015)

Identification and Validation of Three Hub Genes Involved in Cell Proliferation and Prognosis of Castration-Resistant Prostate Cancer
por: Yu, Pan, et al.
Publicado: (2022)

Identification of marker genes and cell subtypes in castration-resistant prostate cancer cells
por: Lin, Xiao-Dan, et al.
Publicado: (2021)

Identification of castration‐resistant prostate cancer‐related hub genes using weighted gene co‐expression network analysis
por: Cheng, Yifei, et al.
Publicado: (2020)

Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer
por: Oshima, Masashi, et al.
Publicado: (2023)

CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine
por: Chen, Xi, et al.
Publicado: (2022)

Gene Expression Profiling Analysis Reveals Putative Phytochemotherapeutic Target for Castration-Resistant Prostate Cancer
por: Rotimi, Solomon Oladapo, et al.
Publicado: (2019)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
por: Xu, Wen, et al.
Publicado: (2023)

Identification of new octamer transcription factor 1‐target genes upregulated in castration‐resistant prostate cancer
por: Yamamoto, Shinichiro, et al.
Publicado: (2019)

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
por: Tan, Winston, et al.
Publicado: (2022)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Novel Gene Signatures Predictive of Patient Recurrence-Free Survival and Castration Resistance in Prostate Cancer
por: A, Jun, et al.
Publicado: (2021)

A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
por: Greasley, Rosa, et al.
Publicado: (2015)

Identification of Key Gene Signatures Associated With Bone Metastasis in Castration-Resistant Prostate Cancer Using Co-Expression Analysis
por: Yu, Zhongxiang, et al.
Publicado: (2021)

A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
por: Wang, Li, et al.
Publicado: (2015)

Sox2 Is an Androgen Receptor-Repressed Gene That Promotes Castration-Resistant Prostate Cancer
por: Kregel, Steven, et al.
Publicado: (2013)

Clinical Characterization of Mismatch Repair Gene-Deficient Metastatic Castration-Resistant Prostate Cancer
por: Ye, Senlin, et al.
Publicado: (2020)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date
por: Chong, Julio T, et al.
Publicado: (2018)

Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin
por: Mak, Blossom, et al.
Publicado: (2022)

Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
por: Zhong, Shangwei, et al.
Publicado: (2021)

Upregulation of erythropoietin and erythropoietin receptor in castration-resistant progression of prostate cancer
por: Ye, Chen, et al.
Publicado: (2019)

Targeting molecular resistance in castration-resistant prostate cancer
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Chemotherapy options in castration-resistant prostate cancer
por: Teply, Benjamin A., et al.
Publicado: (2016)

Effective Combinatorial Immunotherapy for Castration Resistant Prostate Cancer
por: Lu, Xin, et al.
Publicado: (2017)

Targeting mTOR Complex 2 in Castration-Resistant Prostate Cancer with Acquired Docetaxel Resistance
por: Huang, Yujie, et al.
Publicado: (2022)

Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer
por: Matsumoto, Teppei, et al.
Publicado: (2019)

Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer
por: Pang, Xiaocong, et al.
Publicado: (2019)

Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer
por: Chen, Xiaoliang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1q6t5drea03k19ifdmvddvdb1d